Company Description
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.
The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments.
The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices.
The Advanced Circulatory Support segment develops, produces, and sells temporary life support products.
It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers.
The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1987 |
| IPO Date | Feb 10, 1993 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2,900 |
| CEO | Vladimir A. Makatsaria |
Contact Details
Address: 20 Eastbourne Terrace London, X0 W2 6LG United Kingdom | |
| Phone | 4402033250662 |
| Website | livanova.com |
Stock Details
| Ticker Symbol | LIVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001639691 |
| CUSIP Number | G5509L101 |
| ISIN Number | GB00BYMT0J19 |
| Employer ID | 98-1268150 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Alex Shvartsburg | Chief Financial Officer |
| Trui Hebbelinck | Chief Human Resources Officer |
| Vladimir A. Makatsaria | Chief Executive Officer and Director |
| Badri Amurthur | Chief Technology Officer |
| Lindsey Little | Senior Director of Investor Relations |
| Michael D. Hutchinson | Senior Vice President, Chief Legal Officer and Company Secretary |
| Deanna Wilke | Vice President of Corporate Communications |
| Matthew Joseph Dodds III | Senior Vice President of Corporate Development and IT |
| Dr. Bryan D. Olin Ph.D. | Senior Vice President and Head of Product Development - Neuromodulation |
| Ryan Miller | President of Advanced Circulatory Support |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2024 | SD | Form - SD |
| May 3, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| May 3, 2024 | 10-Q | Quarterly Report |
| May 1, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 8, 2024 | 8-K | Current Report |
| Mar 6, 2024 | 8-K | Current Report |